Moreover, when comparing the high and low-methylation groups only, high methylation was a significant predictor of BCR in uni- and multivariate Cox regression analyses in cohort 1 (Table S10), and these results were successfully validated in cohort 2 (Table S10), suggesting that prostate cancer patients can be stratified into clinically relevant subgroups based on RHCG and TCAF1 methylation. This evidence concerns the gene BCR and prostate cancer.